TLTaiyao Li

Taiyao Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taiyao Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Dong

    Department of Neurosurgery, First Affiliated Hospital of Dalian Medical University, Dalian, China

    1 shared publication
  • Jie Wang

    Department of Neurosurgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn

    1 shared publication
  • Xiaoyuan Tian

    Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn

    1 shared publication
  • Yanqin Yang

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    1 shared publication
  • Ying Cao

    Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn

    1 shared publication

Latest Publications

  • Open Access

    A Novel Signature of Disulfidptosis‐Related lncRNAs Predicts Prognosis in Glioma: Evidence From Bioinformatic Analysis and Experiments

    by Taiyao Li, Ying Cao, Jie Wang, Xiaoyuan Tian, Bin Dong, Yanqin Yang

    Glioma is the most common primary malignant brain tumor, characterized by high mortality and poor prognosis. Disulfidptosis, a recently identified form of regulated cell death, has been implicated in tumor progression; however, its role in glioma remains unclear. In this study, we developed and validated a novel prognostic signature based on disulfidptosis‐related long noncoding RNAs (DRLs) by integrating transcriptomic and clinical data from The Cancer Genome Atlas. Seven DRLs were identified to construct a risk model that effectively stratified patients into high‐ and low‐risk groups with significantly different overall survival outcomes. Functional enrichment and immune‐related analyses revealed that the high‐risk group exhibited distinct immune microenvironment features, including altered immune cell infiltration, immune checkpoint expression, and activity of immune‐related pathways, suggesting a potential link between DRLs and immune modulation. Drug sensitivity analysis identified several chemotherapeutic agents and targeted inhibitors with higher predicted efficacy in the high‐risk group, offering insights into personalized treatment strategies. In vitro experiments further demonstrated that LINC02542 knockdown significantly suppressed glioma cell proliferation, migration, and invasion. Collectively, these findings indicate that the DRL signature functions as an independent prognostic indicator and a potential biomarker for immune landscape profiling and immunotherapy response prediction in glioma. This integrative multiomics approach provides novel perspectives for precision immunotherapy and targeted therapy in glioma.